Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 8, 2009, Pages 843-853

  Daperno, M ^a,b   Sostegni, R ^b   Canaparo, R ^c   Serpe, L ^c   Lavagna, A ^b   CrocellA L ^b   Castagno, F ^d   Vernetto, A ^b   Rigazio, C ^b   Ercole, E ^b   D'Antico, S ^d   Pera, A ^b   Zara, G ^d   Rocca, R ^b  

^a AO Ordine Mauriziano   (Italy)

^b Gastroenterology Unit   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Blood Transfusion Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; INFLIXIMAB; MESALAZINE; METHYLMERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT DURATION; WILD TYPE;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; DNA; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70349196312     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04106.x     Document Type: Article

References (52)

1. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005 54 : 237 241.
2. Flasar MH, Johnson T, Roghmann MC, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis 2008 14 : 13 9.
3. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000 : CD000545.
4. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000 : CD000067.
5. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl 1 i16 35.
6. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. JCC 2008 2 : 24 62.
7. Colombel JF, Rutgeerts P, Reinish W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 2008 57 (Suppl II A1.
8. Remy CN. Metabolism of thiopyrimidines and thiopurines S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 1963 238 : 1078 1084.
9. Weinshilboum RM., Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 32 : 651 662.
10. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005 15 : 801 815. (Pubitemid 41531729)
11. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006 25 : 1629 1638.
12. Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008 14 : 265 274.
13. Daperno M, Cagliero E, Sostegni R, et al. Direct costs of inflammatory bowel disease (IBD): A population-based study in north-western Italy. Gastroenterology 2008 134 (4 Suppl 1 A496.
14. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002 16 : 79 85.
15. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001 49 : 656 664.
16. Stocco G, Martelossi S, Malusa N, et al. Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse. Dig Dis Sci 2008 53 : 3246 3249.
17. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995 39 : 456 459.
18. Xin H, Fischer C, Schwab M, Klotz U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005 21 : 1105 1109.
19. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006 12 : 251 257.
20. Lennard L. Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998 20 : 527 531.
21. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005 22 : 605 611.
22. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007 102 : 2747 2753.
23. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006 55 : i1 15.
24. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl A 5 36.
25. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979 77 : 843 846.
26. Frenz MB, Dunckley P, Camporota L, Jewell DP, Travis SP. Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol 2005 100 : 1117 1120.
27. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989 2988 : 2 6.
28. Keizer-Garritsen JJ, Brouwer C, Lambooy LH, et al. Measurement of thiopurine S-methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children. Ann Clin Biochem 2003 40 (Pt 1 86 93.
29. Khalil MN, Erb N, Khalil PN, Escherich G, Janka-Schaub GE. Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes. J Chromatogr B Analyt Technol Biomed Life Sci 2005 821 : 105 111.
30. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998 44 : 551 555.
31. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 126 : 608 614.
32. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001 11 : 275 278.
33. Serpe L, Calvo PG, Muntoni E, et al. Thiopurine S-methyltransferase pharmacogenetics on a large-scale healthy Italian-caucasian population: difference in enzyme activity among infant, children, adolescent and adult subjects. Pharmacogenomics 2009 in press.
34. Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003 18 : 917 925.
35. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 713.
36. Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol 2008 103 : 207 219. quiz 206, 220.
37. Summers RW, Switz DM, Sessions JT Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979 77 (4 Pt 2 847 869.
38. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 86 : 249 266.
39. Mackay IR, Wall AJ, Goldstein G. Response to azathioprine in ulcerative colitis Report of 7 cases. Am J Dig Dis 1966 11 : 536 545.
40. Willoughby JM, Kumar P, Beckett J, Dawson AM. A double-blind trial of azathioprine in Crohn's disease. Gut 1971 12 : 864.
41. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004 13 : 563 567.
42. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008 103 : 1783 1800.
43. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008 27 : 220 227.
44. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000 118 : 1025 1030.
45. Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 2005 54 : 565.
46. Regueiro M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002 35 : 240 244.
47. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005 100 : 2239 2247.
48. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006 24 : 767 781.
49. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 2006 16 : 847 854.
50. Shah JA, Edwards CM, Probert CS. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur J Gastroenterol Hepatol 2008 20 : 169 173.
51. Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007 53 : 1306 1314.
52. Dilger K, Schaeffeler E, Lukas M, et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 2007 29 : 1 5.